Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This paper reports two cases of finasteride-induced melasma, expanding the limited literature on this side effect, and underscores the importance of considering 5-ARI exposure in patients with new or persistent hyperpigmentation, especially among those with darker skin.

In this study, network meta-analyses were used to explore the ranking of various 5-alpha reductase inhibitor regimens on reducing dihydrotestosterone levels and to investigate whether this reduction correlates with increased total hair density in male androgenetic alopecia.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

This study explored the effects of USPlus® DERM, a bioactive fatty acid extract from Serenoa repens, in promoting hair growth and enhancing hair follicle stem cell stemness in an ex vivo setting, showing potential for both 5‐α reductase-dependent and independent hair loss treatments.

This study observed that finasteride, while lowering cholesterol levels, did not decrease the prevalence of clinical cardiovascular events or new ECG abnormalities in men with benign prostatic hyperplasia compared to controls, suggesting a potential disconnect between cholesterol management and cardiovascular risk reduction with this treatment.

This study suggests that using opioids along with 5αRI may reduce opioid use disorder risk in humans, supporting similar findings from animal studies.

This study found that teak leaf extract can be effective in promoting hair growth in males with androgenic alopecia; however, significant variability in steroid 5-alpha reductase inhibitory activity among samples from different geographic origins means quality control is important for consistent therapeutic potential.

This study found that among various treatments for male androgenetic alopecia, dutasteride 0.5 mg/day was the most effective option overall. Additionally, among FDA-approved treatments, topical minoxidil 5% was the most effective topical therapy, and finasteride 1 mg/day was the most effective oral therapy.

This study analyzed reports from the FDA Adverse Event Reporting System and observed an upward trend in suicidality-related safety signals among young male finasteride users since 2019, peaking in 2022, highlighting emerging psychiatric safety concerns and the need for vigilant monitoring of this population.

This source reports that combining 5-alpha reductase inhibitors with minoxidil for treating male androgenic alopecia presents a minimal risk of side effects when administered following established medical guidelines, with finasteride commonly associated with reversible sexual side effects and dutasteride used off-label with similar risks.

This review highlights that 5 Alpha Reductase Inhibitors, used for treating conditions like benign prostatic hypertrophy, can cause side effects that sometimes persist after stopping the medication, urging physicians to consider these drugs as potential sources of new symptoms in patients.

In this review, the researchers reported that 5α-reductase inhibitors demonstrated neuroprotective effects and reduced dyskinesias in animal models of Parkinson's disease, suggesting their potential for repurposing to manage symptoms in men with PD.

This study found that low-dose dutasteride is effective and safe for treating male androgenetic alopecia, showing significant improvement in hair growth and reduction in hair shedding in most patients.

In this study, researchers observed that Finasteride improved cardiac function by enhancing antioxidant levels and reducing oxidative stress in obese and aging rats, though it did not benefit metabolic status and induced insulin resistance in normal diet-fed rats.

This study found that women taking 5α-reductase inhibitors (5aRI) for alopecia had a lower risk of breast cancer compared to those not using these medications, with no increased risk of developing ovarian or endometrial cancer.

In this review, the authors highlight the involvement of the 5α-reductase enzyme family in androgen-dependent disorders, noting the discovery of a novel isoform, SRD5A3, which is overexpressed in cancers with poor prognosis.

5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.

In this study, male Wistar rats with obesity showed reduced depressive-like behaviors, brain inflammation, and oxidative stress after long-term finasteride treatment, suggesting potential benefits of finasteride in obese conditions, while lean rats experienced adverse effects including metabolic disturbances and depressive-like behaviors.

This study observed that chronic and acute exposure to finasteride negatively impacted development, reproduction, and gene expression in Daphnia magna, highlighting the environmental risks of this pharmaceutical for freshwater ecosystems.

This study observed that although 5-alpha-reductase inhibitors reduce PSA density in patients on active surveillance for prostate cancer, those who progress to more serious disease still show higher PSA densities, suggesting these inhibitors accentuate differences in clinically significant cases.

Taking medication for hair loss might cause sexual problems.

This study examined the stability of two 5α-reductase inhibitors in Tectona grandis extracts, finding that they are more stable in acidic environments and degrade rapidly under heat and light unless protected, suggesting the need for careful storage when developing anti-hair loss medications.

This integrative literature review suggests that phytotherapeutic products, like Saw palmetto and Green tea, could serve as viable alternatives to current medications like finasteride for treating androgenetic alopecia, potentially offering fewer side effects.

This study assessed the environmental impact of the drug finasteride on Daphnia magna, finding that both acute and chronic exposure impaired development and reproduction, affected gene expression and metabolism, and altered lipid profiles, highlighting the need to understand pharmaceutical impacts on aquatic ecosystems.

This study found that Solanum nigrum L. extracts showed potential as 5 alpha-reductase inhibitors, similar to finasteride, and highlighted their promise for treating androgenic diseases like benign prostatic hyperplasia and male pattern hair loss.

This study found that male patients with androgenetic alopecia had higher serum levels of Zinc Alpha 2 Glycoprotein than healthy controls, suggesting its potential role in the disease's pathophysiology.

This study developed innovative silica/natural polysaccharide hybrid nanoparticles encapsulating plant-derived 5-alpha-reductase inhibitors, reporting effective controlled release at hair follicle pH and lower cytotoxicity, suggesting a promising delivery system for antiandrogenic treatments.

In this rodent study, researchers found that the drug finasteride may reduce anxiety and depression-like behaviors in a model of aging, despite inducing metabolic disturbances and depressive-like behaviors in young rats, suggesting potential considerations for its use in elderly populations.

In this study, chronic exposure to finasteride induced metabolic disturbances and depression-like behaviors in young male rats, similar to those caused by obesity, but did not worsen anxiety or depression in obese rats.